Protalix Biotherapeutics (PLX)
:PLX
PLX Stock Chart & Stats
$2.29
-$0.05(-2.01%)
At close: 4:00 PM EST
$2.29
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.32 - $3.19
Previous CloseN/A
Volume368.29K
Average Volume (3M)980.85K
Market Cap
$185.31M
Enterprise Value$178.15M
Total Cash (Recent Filing)$30.98M
Total Debt (Recent Filing)$8.32M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
May 08, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding80,571,640
10 Day Avg. Volume730,626
30 Day Avg. Volume980,852
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit6.92
Enterprise Value/Ebitda-44.15
Forecast
1Y Price Target
$12.00Price Target Upside424.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$79.20M
Bulls Say, Bears Say
Bulls Say
Pipeline AdvancementProgression of PRX-115 into a mid-stage trial for gout diversifies the pipeline and could produce a competitively advantaged uric acid–lowering therapy with a wide dosing interval, bolstering long-term commercial prospects.
Regulatory Approval And Label ExpansionEuropean approval of an every-four-weeks dosing option for Elfabrio expands the product label and increases the likelihood that regulators in other regions will accept the same convenient regimen, supporting a larger addressable market.
Treatment Convenience And AdherenceA monthly dosing schedule for Elfabrio offers greater convenience for patients with a chronic condition and may improve treatment adherence, helping the product compete more effectively against established enzyme therapies.
Bears Say
Competitive Landscape In EuropeExisting competing enzyme therapies in the European market may limit the speed and extent of Elfabrio's adoption, reducing the potential market share gains from the dosing-label expansion.
Revenue PerformanceReported product revenue came in below analyst expectations, creating a financial headwind and increasing pressure on earnings visibility.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.32 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $185.31M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is May 08, 2026 which is in 24 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Mar 18, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0.04 by -$0.1.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.01.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of -$0.06 in its last earnings report, missing expectations of $0.04. Following the earnings report the stock price went down -20.789%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (424.02% Upside)
$12.00 (424.02% Upside)
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Fundamentals
Return on Equity
-13.46%
Trailing 12-Months
Asset Growth
12.16%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably EU regulatory approval for a differentiated 4-week Elfabrio dosing regimen), a material $25 million milestone that meaningfully improves near-term liquidity, and active progression of pipeline assets (PRX-115 enrollment). These positive developments were balanced against higher R&D spending (up 51%), a 2025 net loss of $6.6 million versus prior-year income, increased cost of goods sold, and near-term operational and reimbursement timing risks across EU countries and uncertainty around U.S. label changes. Overall, the company appears well positioned financially and clinically going into 2026 due primarily to the milestone and partner execution, although investors should watch cash burn, R&D spending, and timing of commercial rollout.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(424.02% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.88% Insiders
2.65% Mutual Funds
4.20% Other Institutional Investors
85.24% Public Companies and
Individual Investors